Leveraging more than 25 years of experience, Rob provides a wide range of corporate and securities legal services to innovative late-stage and public companies in the technology and life sciences industries. He represents issuers and underwriters in public offerings and private placements of equity and debt securities. Rob also advises boards and management as an outside general counsel on day-to-day corporate and securities matters, including corporate governance, public company reporting and stock exchange rules and requirements.
Rob co-chairs Fenwick’s capital markets and public companies group, helping clients raise capital, navigate risk and tell a story through filings and disclosures over the long-term. For example, he represented Loxo Oncology in its initial public offering, multiple follow-on offerings and its $8 billion acquisition by Eli Lilly. He has also represented Dexcom, a leader in continuous glucose monitoring, for more than 15 years, from its IPO in 2005 to numerous public offerings and its $850 million convertible senior notes offering in 2018. The transactions illustrate Rob’s commitment to a company’s myriad legal needs through its full lifecycle.
Ranked as a top capital markets lawyer by Chambers USA, Rob is regularly sought after for his thought leadership. He is a lead author of the firm’s Technology and Life Sciences IPO Survey and co-chairs the Practising Law Institute’s How to Prepare an Initial Public Offering 2019 program.